Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Frequentist and Bayesian analysis methods for case series data and application to early outpatient COVID-19 treatment case series of high risk patients
Gkioulekas et al., Authorea, Inc., doi:10.22541/au.164745391.17821933/v2 (Preprint)
Gkioulekas et al., Frequentist and Bayesian analysis methods for case series data and application to early outpatient COVID-19.., Authorea, Inc., doi:10.22541/au.164745391.17821933/v2 (Preprint)
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Hybrid statistical framework for evaluating treatment protocols. COVID-19 treatment protocols often use risk stratification, multiple treatments, and customization based on the disease stage and the patient. Authors find strong evidence for the efficacy of the early outpatient treatment protocols considered.
Gkioulekas et al., 16 May 2022, retrospective, preprint, 3 authors.
Contact: drlf@hushmail.com, peteramccullough@gmail.com, zz613@hotmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: submitted to Reviews in Cardiovascular Medicine Frequentist and Bayesian analysis methods for case series data and application to early outpatient COVID-19 treatment case series of high risk patients Eleftherios Gkioulekas, Ph.D. Professor, School of Mathematical and Statistical Sciences, University of Texas Rio Grande Valley, Edinburg, TX, United States∗ Peter A McCullough, MD, MPH Chief Medical Advisor, Truth for Health Foundation, Tucson AZ, United States† Vladimir Zelenko, MD Affiliate Physician, Columbia University Irving Medical Center, New York City, NY, United States‡ When confronted with a public health emergency, significant innovative treatment protocols can sometimes be discovered by medical doctors at the front lines based on repurposed medications. We propose a very simple hybrid statistical framework for analyzing the case series of patients treated with such new protocols, that enables a comparison with our prior knowledge of expected outcomes, in the absence of treatment. The goal of the proposed methodology is not to provide a precise measurement of treatment efficacy, but to establish the existence of treatment efficacy, in order to facilitate the binary decision of whether the treatment protocol should be adopted on an emergency basis. The methodology consists of a frequentist component that compares a treatment group against the probability of an adverse outcome in the absence of treatment, and calculates an efficacy threshold that has to be exceeded by this probability, in order to control the corresponding p-value, and reject the null hypothesis. The efficacy threshold is further adjusted with a Bayesian technique, in order to also control the false positive rate. A selection bias threshold is then calculated from the efficacy threshold to control for random selection bias. Exceeding the efficacy threshold establishes efficacy by the preponderance of evidence, and exceeding the more demanding selection bias threshold establishes efficacy by the clear and convincing evidentiary standard. The combined techniques are applied to case series of high-risk COVID-19 outpatients, that were treated using the early Zelenko protocol and the more enhanced McCullough protocol. The resulting efficacy thresholds are then compared against our prior knowledge of mortality and hospitalization rates of untreated high-risk COVID-19 patients, as reported in the research literature. Keywords: COVID-19; SARS-CoV-2; ambulatory treatment; early treatment, mortality; hospitalization; epidemiology; biostatistics; drug repurposing.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit